Lc2 ad cells

Manufactured by Merck Group

Lc2/ad cells are a type of cell line used in laboratory research. They are derived from human embryonic kidney cells and are commonly used as a model system for various biological studies. The core function of Lc2/ad cells is to provide a reliable and well-characterized cell line for experimental purposes, but a detailed description of their intended use or specific applications is not available.

Automatically generated - may contain errors

Lab products found in correlation

Sw480, by American Type Culture Collection (1 mentions) Sw620, by American Type Culture Collection (1 mentions) Cabozantinib, by Selleck Chemicals (1 mentions) Afatinib, by Selleck Chemicals (1 mentions) Foretinib, by Selleck Chemicals (1 mentions) Ponatinib, by Selleck Chemicals (1 mentions) Pegfr y1068, by Cell Signaling Technology (1 mentions) Gefitinib, by Selleck Chemicals (1 mentions) Trametinib, by Selleck Chemicals (1 mentions) N ras f155, by Santa Cruz Biotechnology (1 mentions) Perk1 2 xp t202 y204, by Cell Signaling Technology (1 mentions) Pegfr y1173, by Cell Signaling Technology (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions)

2 protocols using lc2 ad cells

Cell Lines and Reagents

Check if the same lab product or an alternative is used in the 5 most similar protocols

Informed consents for diagnostic testing and therapy were obtained from patients involved in this study. SW48, SW480 and SW620 cells were obtained from American Type Culture Collection (ATCC; Manassas, VA). Lc2/ad cells were obtained from Sigma-Aldrich (St. Louis, MO). We transduced SW48 cells with pCCL-KRAS^12V lentivirus to obtain SW48-KRAS^12V cells. All cells were thawed from frozen stocks expanded from original cells obtained from ATCC and cultured for less than 3 months in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum. Regorafenib, vandetanib and lenvatinib were obtained from Selleck pharmaceutical (Houston, TX).

Le Rolle A.F., Klempner S.J., Garrett C.R., Seery T., Sanford E.M., Balasubramanian S., Ross J.S., Stephens P.J., Miller V.A., Ali S.M, & Chiu V.K. (2015). Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget, 6(30), 28929-28937.

+ Open protocol

+ Expand

Cell Line Authentication and Kinase Inhibitor Assay

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

LC-2/ad cells were obtained from Sigma (cat no. 94072247), TPC1 cells obtained from R.E. Schweppe (17 (link)); H2228 cells obtained from J.D. Minna. HCC78-TAER were previously described (18 (link)). Cells were maintained in RPMI-1640 (Invitrogen) with 10% FBS at 37°C in a humidified 5% CO₂ incubator. Fingerprint analysis of cell lines was performed bi-annually by the Molecular Biology Service Center at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus in Aurora, CO to ensure authenticity. Alectinib was provided by Chugai Pharmaceuticals. Ponatinib, cabozantinib, trametinib, gefitinib, afatinib, and foretinib were obtained from Selleck Chemicals. Pervanadate was generated by incubating hydrogen peroxide with 100 mM sodium orthovanadate in distilled water. Antibodies used were as follows: pEGFR Y1068 (D7A5), pEGFR Y1173 (53A5), total RET (D3D8R), pERK1/2 XP T202/Y204 (D13.14.4E), total ERK1/2 (L34F12), pAKT S473 XP (D9E), total AKT (40D4), and pSHC1 Y239/Y240 (2434) from Cell Signaling; pTYR (4G10 Platinum), GAPDH (6C5) and GAPDH (ABS16) from Millipore; pRET Y1062, α-tubulin (TU-02) and NRAS (F155) from Santa Cruz Biotechnology.

Nelson-Taylor S.K., Le A.T., Yoo M., Schubert L., Mishall K.M., Doak A., Varella-Garcia M., Tan A.C, & Doebele R.C. (2017). Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. Molecular cancer therapeutics, 16(8), 1623-1633.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!